These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17077140)

  • 1. Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo.
    Kennedy JA; Barabé F; Patterson BJ; Bayani J; Squire JA; Barber DL; Dick JE
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16930-5. PubMed ID: 17077140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the TEL-Syk fusion protein in hematopoietic stem cells leads to rapidly fatal myelofibrosis in mice.
    Graham MT; Abram CL; Hu Y; Lowell CA
    PLoS One; 2013; 8(10):e77542. PubMed ID: 24116232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.
    James C; Mazurier F; Dupont S; Chaligne R; Lamrissi-Garcia I; Tulliez M; Lippert E; Mahon FX; Pasquet JM; Etienne G; Delhommeau F; Giraudier S; Vainchenker W; de Verneuil H
    Blood; 2008 Sep; 112(6):2429-38. PubMed ID: 18612101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
    Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR;
    Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
    Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; Gilliland DG
    Blood; 2006 Jun; 107(11):4274-81. PubMed ID: 16478879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.
    Schwaller J; Frantsve J; Aster J; Williams IR; Tomasson MH; Ross TS; Peeters P; Van Rompaey L; Van Etten RA; Ilaria R; Marynen P; Gilliland DG
    EMBO J; 1998 Sep; 17(18):5321-33. PubMed ID: 9736611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique differentiation programs of human fetal liver stem cells shown both in vitro and in vivo in NOD/SCID mice.
    Nicolini FE; Holyoake TL; Cashman JD; Chu PP; Lambie K; Eaves CJ
    Blood; 1999 Oct; 94(8):2686-95. PubMed ID: 10515872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.
    Takeda Y; Nakaseko C; Tanaka H; Takeuchi M; Yui M; Saraya A; Miyagi S; Wang C; Tanaka S; Ohwada C; Sakaida E; Yamaguchi N; Yokote K; Hennighausen L; Iwama A
    Br J Haematol; 2011 Jun; 153(5):589-98. PubMed ID: 21492125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoiesis in the absence of janus-kinase 2: BCR-ABL induces red cell formation in JAK2(-/-) hematopoietic progenitors.
    Ghaffari S; Kitidis C; Fleming MD; Neubauer H; Pfeffer K; Lodish HF
    Blood; 2001 Nov; 98(10):2948-57. PubMed ID: 11698276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
    Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.
    Ishii T; Zhao Y; Sozer S; Shi J; Zhang W; Hoffman R; Xu M
    Exp Hematol; 2007 Nov; 35(11):1633-40. PubMed ID: 17764815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
    Shi J; Yuan B; Hu W; Lodish H
    Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.
    Yao H; Ma Y; Hong Z; Zhao L; Monaghan SA; Hu MC; Huang LJ
    Leukemia; 2017 Oct; 31(10):2122-2131. PubMed ID: 28057939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation.
    Bäsecke J; Schwieger M; Griesinger F; Schiedlmeier B; Wulf G; Trümper L; Stocking C
    Leuk Lymphoma; 2005 Feb; 46(2):265-72. PubMed ID: 15621811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.
    Monni R; Santos SC; Mauchauffe M; Berger R; Ghysdael J; Gouilleux F; Gisselbrecht S; Bernard O; Penard-Lacronique V
    Oncogene; 2001 Feb; 20(7):849-58. PubMed ID: 11314018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD133 marks a stem cell population that drives human primary myelofibrosis.
    Triviai I; Stübig T; Niebuhr B; Hussein K; Tsiftsoglou A; Fehse B; Stocking C; Kröger N
    Haematologica; 2015 Jun; 100(6):768-79. PubMed ID: 25724578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.
    Lacout C; Pisani DF; Tulliez M; Gachelin FM; Vainchenker W; Villeval JL
    Blood; 2006 Sep; 108(5):1652-60. PubMed ID: 16670266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.